Pharmaceuticals, Biotechnology & Life Sciences

IQVIA’s former CFO joins Moderna’s board to boost finance strategy and vaccine pipeline growth, adding deep life‑sciences expertise to the company’s leadership.

GSK’s phase‑III lung‑cancer win with Riz‑Rez and new China partnerships boost its oncology pipeline and share price, while shedding Alector to focus on high‑impact therapies.

BioSyent, Inc. leverages license and regulatory expertise to drive growth in Canada’s specialty pharma sector, offering investors a solid track record and future potential.

Satellos Bioscience’s SAT‑3247 shows breakthrough muscle‑regeneration results in DMD, boosting investor confidence and pricing the stock for a potential game‑changing therapy.

Ocugen, the biotech pioneer targeting cartilage regeneration and joint health, offers investors a glimpse into clinical‑stage innovation and future market potential.

Michael McDonnell’s move from Biogen to Moderna’s board brings seasoned finance leadership, boosting Moderna’s mRNA pipeline while underscoring Biogen’s talent‑driven biotech influence.

Biohaven’s $160 M ARPA‑H grant, leadership overhaul and RISE3 trial milestone signal a bold shift toward breakthrough neurology and immunology drugs.

HSPharm’s phase‑III win: Riz‑Rez boosts overall survival in advanced NSCLC, a breakthrough that could reshape China’s oncology market and lift investor confidence.

Explore Eli Lilly’s 2026 highlights: new Alzheimer’s tests, weight‑loss surge, Canadian eczema approval, and EU price‑pressure challenges.

Discover how Beijing SL Pharmaceutical’s genetic‑engineering pipeline could surge amid China’s biotech boom and new 30‑day FDA review pathway.